2 Day Training Course on the FDA (Food and Drug Administration) Drug Approval Process: June 14-15, 2023
15 juin 2023 04h13 HE
|
Research and Markets
Dublin, June 15, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
IBT offentliggör prospekt
13 juin 2023 05h15 HE
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
IBT publishes prospectus
13 juin 2023 05h15 HE
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
Extra bolagsstämma i Infant Bacterial Therapeutics
09 juin 2023 05h04 HE
|
Infant Bacterial Therapeutics AB
På extra bolagsstämman i Infant Bacterial Therapeutics AB (publ) den 9 juni 2023 beslutades att godkänna styrelsens beslut från den 16 maj 2023 om att bolagets aktiekapital ska ökas genom emission av...
Extraordinary General Meeting of Infant Bacterial Therapeutics
09 juin 2023 05h04 HE
|
Infant Bacterial Therapeutics AB
At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors’ resolution from May 16, 2023 to increase the...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
26 mai 2023 16h05 HE
|
Biodexa Pharmaceuticals PLC
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
24 mai 2023 08h40 HE
|
Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
Global Orphan Diseases Partnering 2010-2023: the Full Collection of Orphan Diseases Disease Deals Signed Between the World's Pharmaceutical and Biotechnology Companies Since 2010
24 mai 2023 07h03 HE
|
Research and Markets
Dublin, May 24, 2023 (GLOBE NEWSWIRE) -- The "Global Orphan Diseases Partnering 2010-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.Global...
Posting of Annual Report & Notice of AGM
22 mai 2023 16h15 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
The FDA (Food and Drug Administration) Drug Approval Process Training Course: A Practical Insight into FDA Requirements
22 mai 2023 04h28 HE
|
Research and Markets
Dublin, May 22, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...